Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc + Iron + Calcium (marketed under the brand name Chengzhang Sanbao) is an approved oral combination mineral supplement developed by Guangdong Hongshanhu Pharmaceutical. The product is a compound oral solution formulated with three active mineral salts: ferrous gluconate, zinc gluconate, and calcium gluconate, along with vitamin B2 (riboflavin) as a co-ingredient. It is specifically indicated for the treatment and prevention of diseases caused by deficiencies in zinc, iron, and calcium, primarily in pediatric populations including infants from six months of age. The formulation provides these essential trace elements in a sweet-sour liquid form to improve compliance in children and directly replenish mineral stores necessary for healthy growth and development. It is an approved pharmaceutical product in China under the '国药准字' regulatory category.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc + iron + calcium.